Personalized Normative Feedback for Stigma and Help-seeking

August 31, 2026 updated by: Han Oh

Developing a Personalized Normative Feedback Intervention to Increase Help-seeking for Suicidal Thoughts

People tend to care about what others think and often change our behaviors accordingly. But what if people do not have an accurate understanding of what others really think? Stigma is pervasive, especially in the Black and Asian American communities, which can prevent people from seeking help. This study explores whether correcting misperceptions (by showing what people really think) about depression and suicide can increase help-seeking behaviors among Black and Asian emerging adults who have untreated depression and suicidal thoughts.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Suicide rates have increased for Black and Asian American emerging adults in California, untreated depression contributes to this concerning trend. A major deterrent to treatment utilization is stigma, which has been known to decrease help-seeking behaviors. Black and Asian American communities have been known to have higher levels of mental health stigma than their white counterparts. People with untreated depression and suicidal thoughts often turn to the internet for help, meaning online interventions can play a crucial role in nudging individuals toward help-seeking. Personalized Normative Feedback (PNF) is one such intervention that has been widely used to modify a range of health behaviors. The premise of PNF is that people generally hold exaggerated views about what their peers deem acceptable (i.e., perceived social norms), which in turn influences behavior. However, perceptions that are so often passively accepted can be challenged with gentle confrontation. PNF actively corrects these views by providing accurate information about what people actually think is acceptable, thus re-routing the social pressure toward conformity to the healthier behavior. Working closely with a community advisory board, we use survey data we collected on social norms from Black and Asian American emerging adults aged (18-29) and explore the extent to which presenting these social norms can increase help-seeking intentions and behaviors. This study will identify Black (N=80) and Asian American (N=80) emerging adults with untreated depression and/or recent suicidal ideation but have expressed no intention to seek help, and within each racial group, randomly assign half to a PNF treatment and half to the control condition. This study will test whether the PNF intervention will decrease stigma, increase intention to seek treatment, and one month later, test whether the intervention led to help-seeking behaviors. This study will also collect survey data on the acceptability, safety, and feasibility of PNF. If efficacious, the researchers expect to be able to administer this cost-effective, quick, and easy intervention to thousands of individuals to reduce stigma and increase help-seeking.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
160

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Hans Oh, PhD
  • Phone Number: (213) 821-1382
  • Email: hansoh@usc.edu

Study Locations

  • United States
    • California
      • Los Angeles, California, United States, 90089
        • USC School of Social Work
        • Contact:
        • Principal Investigator:
          • Hans Y. Oh, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Adults aged 18-29
  • Asian American
  • Black American
  • Suicidal ideation
  • Depression
  • Not currently in treatment
  • English speaking

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: PNF Treatment
In this survey experiment, participants will receive information on the social norms data, such as information about whether other people would be friends with someone in mental health treatment.
Behavioral: Personalized Normative Feedback (PNF)
Presenting participants with information about their perceptions of social norms, and actual data on social norms, while highlighting discrepancies, and gently confronting participants toward behavioral changes.
Active Comparator: Control
An attention control (presenting information about artificial intelligence)
Behavioral: Attention control
The participants will engage in an activity online for the same duration as the intervention.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Number of participants who express intention to to seek help
Time Frame: Since the intervention occurs on a single day, the assessment will take place at baseline, and then immediately following the intervention (post-test), and then 30 days after as a follow-up assessment.
Participants will rate their intention to seek help from 12 different sources (e.g., family member, partner, pastor, friend, 9-8-8); each source will be rated using an four category ordinal item ranging from 'definitely won't do this' to 'definitely will do this'.
Since the intervention occurs on a single day, the assessment will take place at baseline, and then immediately following the intervention (post-test), and then 30 days after as a follow-up assessment.
Number of participants who engage engage in help-seeking behaviors
Time Frame: 30 day follow-up
Actually contacting one of 12 sources of help, including contacting a provider, talking to a friend, talking to a pastor, calling 9-8-8.
30 day follow-up
Perceived public stigma
Time Frame: The intervention takes place on a single day, and so the assessments will occur at baseline and immediately following the intervention (post-test) on the same day, and then 30-day follow-up.
The Discrimination and Devaluation Scale will be administered through a survey and assess whether people perceive their social norms (public stigma) differently. The 12 items in the scale will be averaged and will range from 0-3, with higher values indicating greater perceived public stigma.
The intervention takes place on a single day, and so the assessments will occur at baseline and immediately following the intervention (post-test) on the same day, and then 30-day follow-up.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Han Oh

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Hans Oh, PhD, University of Southern California

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • Link, B. G., Cullen, F. T., Frank, J., & Wozniak, J. F. (1987). The social rejection of former mental patients: Understanding why labels matter. American journal of Sociology, 92(6), 1461-1500.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 30, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 1, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 25, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 27, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 6, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 3, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 31, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • UP-24-00999

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings